Welcome to EQUITY DEVELOPMENT

The UK's longest established regulated provider of sponsored equity research.

We launched EQUITY DEVELOPMENT in 1997 becoming the first ever  regulated provider of Sponsored Equity Research in the UK.

Our research teams are made up of expert analysts with deep understanding & experience in their sectors.  Our research is distributed to all relevant investment classes & commentators. (at no cost to the reader).

We have made our name by specialising in those companies who are not receiving the attention that they merit, using detailed commentary, appropriate valuation metrics and regular publications to help eradicate undervaluation in the medium term.

 

FREE REGISTRATION

Sign up today and access the very latest company research

LOG IN

For access to all company research please

Cobra Biomanufacturing Plc

Cobra Biomanufacturing Plc (Cobra) is a “pure player”, independent, full-service cGMP, custom biopharmaceutical manufacturer providing pre-clinical and clinical trial material and in-market supply to mainly small to medium sized drug discovery companies.

Timing is of the essence

Fundraising of £1.2m covers short term working capital and capital investment primarily at it’s Oxford facility

Newer contracts are showing longer lead times for revenues

Consequently return to profits now seen in 2011

Fair value put at 23p / share on successful execution

Publication Date:
June 9 2008

H1 results

Sales +24%

Full year downgrade

New target price 59p

Publication Date:
July 5 2007

Cobra; delivering profitability

  • 20% increase in forward order book
  • Strengthening of Senior Management team
  • Increasing global presence
  • Modernising manufacturing facilities
  • Fair price of 75p vs current 45p

Publication Date:
January 9 2007

Cobra Biomanufacturing; moving out of the undergrowth (profitability in 06)

  • Pure play in sector
  • Operates in high growth market segment
  • Strong presence already in key North America market
  • Profitability expected in 2006
  • Discounted PER valuation shows upside potential

 

 

 

Publication Date:
April 5 2006